Professor Robert Hills
- The Early Breast Cancer Trialists' Collaborative Group (EBCTCG)
- A comparison of individual patient data (IPD) over meta-analyses of published data, implications for clinical trial design and the utility of endpoints for early breast cancer trials. CRUK STUDENTSHIP AVAILABLE
- Assessing benefits and harms in early breast cancer: predictive and prognostic factors in early breast cancer and long-term side-effects of therapy. CRUK STUDENTSHIP AVAILABLE
Professor of Medical Statistics
Robert Hills studied mathematics at the University of Oxford, where his DPhil was on exploration of symmetries with applications to superconductivity. He joined the CTSU in 1993 as a programmer on the QUASAR trial in colorectal cancer. Following a brief period working in low temperature physics at the University of Nottingham, he moved to the University of Birmingham Clinical Trials Unit (BCTU) in 1997.There, he worked on clinical trials in Acute Myeloid Leukaemia, Alzheimer’s Disease, women’s health and many others as well as large scale individual patient data meta-analyses of treatment for colorectal cancer.
In 2006, he moved to Cardiff University as statistical lead for the NCRI/MRC trials in Acute Myeloid Leukaemia. During his 12 years in Cardiff he was head of the Haematology Clinical Trials Unit, and latterly led on clinical cancer research methodology and haematological malignancies. The novel designs used in these trials allow the clinical value of disease monitoring to be evaluated, as well as numerous targeted therapies in designs that allow for an early change from an unpromising new therapy to one with greater potential. Additionally, he continued his work on the integration of laboratory and clinical data, and on individual patient data meta-analyses, where he demonstrated a survival benefit for gentuzumab ozogamicin in AML.
In 2018, he moved back to the University of Oxford where he is part of the Early Breast Cancer Trialists' Collaborative Group.
A randomised evaluation of low-dose cytosine arabinoside plus lenalidomide versus single-agent low-dose cytosine arabinoside in older patients with acute myeloid leukaemia: Results from the LI-1 trial.
Copland M. et al, (2023), Br J Haematol
Acute myeloid leukaemia in Afghanistan: Understanding an unfamiliar landscape.
Hills RK., (2023), Br J Haematol
Fractionated Versus Single Dose Gemtuzumab Ozogamicin with Determinants of Benefit in Older AML: UK NCRI AML18 Trial.
Freeman SD. et al, (2023), Blood
Do tumor infiltrating lymphocytes (TILs) predict benefits from trastuzumab therapy for HER2 positive breast cancer? Meta-analysis of individual patient data from 4097 women in 5 trials.
Hills RK. et al, (2023), Journal of Clinical Oncology, 41, 508 - 508
Anthracycline-containing and taxane-containing chemotherapy for early-stage operable breast cancer: a patient-level meta-analysis of 100 000 women from 86 randomised trials.
Early Breast Cancer Trialists’ Collaborative Group (EBCTCG). Electronic address: firstname.lastname@example.org None. and Early Breast Cancer Trialists’ Collaborative Group (EBCTCG) None., (2023), Lancet, 401, 1277 - 1292